In diet-induced NASH mice, IL-33 treatment enhanced activity of CPT-I (Figure 6a) and mRNA expression of PPARα (Figure 6b), ACO (Figure 6c), L-FABP (Figure 6g), MTP (Figure 6h) and ABCA-1 (Figure 6i), and reduced mRNA expression of CD36 (Figure 6d), FAS (Figure 6e), and SREBP-1c (Figure 6f). Here, IL33 is linked to metabolic dysfunction-associated steatohepatitis.